6-amino-2-methyl-hexanoic acid | 17377-71-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 6-amino-2-methyl-hexanoic acid
• 英文别名: 6-Amino-2-methyl-hexansaeure；(+/-)-6-Amino-2-methylhexansaeure；6-Azaniumyl-2-methylhexanoate
• CAS: 17377-71-8；54572-27-9
• 化学式: C₇H₁₅NO₂
• 分子量: 145.202
• InChiKey: OSWFAPORICMGLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  、 3,5-二甲基吡唑-1-硝酸咪 、 5-[6-(Diaminomethylideneazaniumyl)hexanoylamino]pentanoate 、 6-amino-2-methyl-hexanoic acid 、 N-Butyloxycarbonyl-ε-amino-capronsaeure 、 5-氨基-2-甲基戊酸 、 n-(Butyloxycarbonyl)-5-aminovaleric acid 、 胍-2-阳离子 在 final compounds 作用下， 生成 6-[6-(Diaminomethylideneazaniumyl)hexanoylamino]hexanoate
  参考文献：
  名称：

  Peptides containing the motif IGD and their use as cell migration modulators

  摘要：

  相对分子质量小于15000的化合物，其中包含肽Ile-Gly-Asp（IGD）或其肽或非肽模拟物。这些化合物可用于调节细胞迁移，并在血管生成中有用。

  公开号：

  US07109160B1
• 作为产物：
  描述：

  3-甲基己内酰胺 在 硫酸 作用下， 生成 6-amino-2-methyl-hexanoic acid
  参考文献：
  名称：

  Schaeffler; Ziegenbein, Chemische Berichte, 1955, vol. 88, p. 1374,1377

  摘要：

  DOI：

文献信息

• [EN] COMPOSITIONS AND METHODS FOR INHIBITING PROTEIN EMBRYONIC ECTODERM DEVELOPMENT ACTIVITY AND TREATING DISEASE<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR L'INHIBITION DE L'ACTIVITÉ DE DÉVELOPPEMENT D'ECTODERME EMBRYONNAIRE DE PROTÉINE ET DE TRAITEMENT D'UNE MALADIE
  申请人：EXO THERAPEUTICS INC

  公开号：WO2021195183A1

  公开（公告）日：2021-09-30

  The invention provides compounds that are inhibitors of the protein embryonic ectoderm development (EED), pharmaceutical compositions, their use in modulating the activity of EED, and their use in the treatment of medical disorders, such as cancer. The invention further provides methods of treating medical disorders, such as cancer, and covalently modifying and/or modulating the activity of EED, using an agent that reacts with, and forms a covalent bond to, cysteine324 of EED.

  这项发明提供了抑制蛋白胚胎外胚层发育（EED）的化合物，药物组合物，它们在调节EED活性中的应用，以及它们在治疗癌症等医学疾病中的应用。该发明还提供了治疗医学疾病（如癌症）的方法，并利用一种与EED的半胱氨酸324发生反应并形成共价键的试剂，对EED进行共价修饰和/或调节活性。
• Inhibitors of Protein Tyrosine Kinase Activity
  申请人：Raeppel Stëphane

  公开号：US20110257100A1

  公开（公告）日：2011-10-20

  This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions.

  本发明涉及抑制蛋白酪氨酸激酶活性的化合物。特别是，本发明涉及抑制生长因子受体的蛋白酪氨酸激酶活性的化合物，从而抑制受体信号传导，例如，抑制VEGF受体信号传导。本发明还提供了用于治疗细胞增殖性疾病和条件以及眼科疾病、障碍和条件的化合物、组合物和方法。
• BIO-INSPIRED AND ANTIMICROBIAL POLYMERS CONTAINING AMINO ACID-LIKE MONOMER BUILDING BLOCKS
  申请人：Joy Abraham

  公开号：US20170172147A1

  公开（公告）日：2017-06-22

  Methods for killing a microbial are provided that include introducing a functionalized amide polymer to a microbe, where the functionalized amide polymer includes a polymer backbone selected from polyesters and polyurethanes; an amide group with a pendant functional group, where the nitrogen atom of the amide group is part of the polymer backbone; and a net positive charge.

  提供了一种杀灭微生物的方法，包括向微生物引入一个功能化酰胺聚合物，其中该功能化酰胺聚合物包括从聚酯和聚氨酯中选择的聚合物骨架；一个带有挂链功能基团的酰胺基团，其中酰胺基团的氮原子是聚合物骨架的一部分；以及净正电荷。
• [EN] COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS<br/>[FR] COMPOSÉS POUR LA RÉDUCTION DE LA VISCOSITÉ DE FORMULATIONS BIOLOGIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2019050780A1

  公开（公告）日：2019-03-14

  The present invention relates to pegylated amino acid compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3A, R3B and n are as defined herein. The present invention also relates to compositions which comprise a pegylated amino acid compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, in combination with a high concentration of an active biological ingredient (ABI). In embodiments of the invention, the ABI is an anti-PD-1 antibody or antigen binding fragment thereof that specifically binds human programmed death receptor 1 (PD-1). The invention further relates to methods for lowering the viscosity of an aqueous solution of a pharmaceutical composition comprising adding a compound of the invention to the solution. The invention also provides methods for treating a pathological disease or condition, such as cancer, by administering to a subject in need of such treatment a therapeutically effective amount of a pharmaceutical composition of the invention.

  本发明涉及公式（I）的聚乙二醇化氨基酸化合物及其药学上可接受的盐，其中X、R1、R2、R3A、R3B和n如本文所定义。本发明还涉及包含本发明的聚乙二醇化氨基酸化合物或其药学上可接受的盐以及药学上可接受的载体的组合物，与高浓度的活性生物成分（ABI）结合。在本发明的实施例中，ABI是特异性结合人类程序性死亡受体1（PD-1）的抗PD-1抗体或其抗原结合片段。本发明还涉及降低含有本发明化合物的药物组合物水溶液粘度的方法，包括向溶液中添加本发明的化合物。本发明还提供了治疗病理性疾病或病况（如癌症）的方法，通过向需要此类治疗的受试者投予本发明的药物组合物的治疗有效量。
• Novel Triazene Compounds For The Treatment Of Cancer
  申请人：Reiter Rudolf

  公开号：US20100234327A1

  公开（公告）日：2010-09-16

  The present invention relates to novel triazene compounds, to a process for their preparation, to pharmaceutical compositions comprising them, and to the use thereof in the treatment of cancer diseases in humans. The novel triazene compounds are distinguished, as compared with the known triazene compounds, by improved activity while at the same time having reduced toxicity, that is to say by fewer side-effects.

  本发明涉及新型三氮烯化合物，以及它们的制备方法、包含它们的药物组合物，以及它们在治疗人类癌症疾病中的用途。这些新型三氮烯化合物与已知的三氮烯化合物相比，具有更好的活性，同时毒性降低，即副作用更少。